The uninvited guests of our microbiome: Helicobacter pylori and Epstein-Barr virus and their role in gastric cancerogenesis
References
- NIH Human Microbiome Project http://www.hmpdacc.org (03.06.2020)
- Sender R., Fuchs S., Milo R.: Revised estimates for the number of human and bacteria cells in the body. PLoS Biol., 2016; 14: e1002533
- Rowan-Nash A.D., Korry B.J., Mylonakis E., Belenky P.: Cross-domain and viral interactions in the microbiome. Microbiol. Mol. Biol. Rev., 2019; 83: e00044-18
- Warren J.R., Marshall B.: Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet, 1983; 1: 1273-1275
- Hallen-Adams H.E., Suhr M.J.: Fungi in the healthy human gastrointestinal tract. Virulence, 2017; 8: 352-358
- Huseyin C.E., O’Toole P.W., Cotter P.D., Scanlan P.D.: Fortotten fungi – the gut mycobiome in human health and disease. FEMS Microbiol. Rev., 2017; 41: 479- 511
- Massarrat S., Saniee P., Siavoshi F., Mkhtari R., Mansour-Ghanaei F., Khalili-Samani S.: The effect of Helicobacter pylori infection, aging and consumption of proton pump inhibitor on fungal colonization in the stomach of dyspeptic patients. Front. Microbiol., 2016; 7: 801
- Wang Z.K., Yang Y.S., Stefka A.T., Sun G., Peng L.H.: Review article: Fungal microbiota and digestive diseases. Aliment. Pharmacol. Ther., 2014; 39: 751-766
- Khosravi Y., Gan H.M., Chia P.J., Croft L.J., Ng C.G., Goh K.L., Vellasamy K.M., Mariappan V., Ong K.C., Wong K.T., et al.: The gastric microbiome of four Malaysian gastroduodenal disease patients. Arch. Gene Genome Res., 2017; 1: 1-9
- Wołkowicz T., Januszkiewicz A., Szych J.: Gut microbiome and its dysbiosis as an important factor influencing the human health condition. Med. Dośw. Mikrobiol., 2014; 66: 223-235
- Huffnagle G.B., Noverr M.C.: The emerging world of the fungal microbiome. Trends Microbiol., 2013; 21: 334-341
- Karczewska E., Wojtas I., Trojanowska D., Budak A., Zwolinska-Wcisło M., Wilk A.: Assessment of co-existence of Helicobacter pylori and Candida fungi in diseases of the upper gastrointestinal tract. J. Physiol. Pharmacol., 2009; 60: 33-39
- Lincoñir-Campos P., Merino-Barrera J.S., Smith C.T., Garcia-Cancino A.: Candida sp. as a potential reservoir and transmission facilitator of Helicobacter pylori. Biomed. J. Sci. & Tech. Res., 2018; 4: 3736-3738
- Fol M., Jachowicz E.: Czynniki zakaźne w procesie nowotworzenia. Med. Og. Nauk. Zdr., 2016; 22: 7-14
- Armstrong H., Bording-Jorgensen M., Dijk S., Wine E.: The complex interplay between chronic inflammation, the microbiome and cancer: Understanding disease progression and what we can do to prevent it. Cancers, 2018; 10: 83
- Abbas M.K., Zaidi A.R.Z., Robert C.A., Thiha S., Malik B.H.: The safety of long-term daily usage of a proton pump inhibitor: A literature review. Cereus, 2019; 11: e5563
- Jump R.L.: Clostridium difficile infection in older adults. Aging Health, 2013; 9: 403-414
- Cheung K.S., Leung W.K.: Risk of gastric cancer development after eradication of Helicobacter pylori. World J. Gastrointest. Oncol., 2018; 10: 115-123
- Joo M.K., Park J.J., Chun H.J.: Proton pump inhibitor: The dual role in gastric cancer. World J. Gastroenterol., 2019; 25: 20582070.
- Global Burden of Disease Cancer Collaboration, Fitzmaurice C., Allen C., Barber R.M., Barregard L., Bhutta Z.A., Brenner H., Dicker D.J., Chimed-Orchir O., Dandona R., et al.: Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the global burden of disease study. JAMA Oncol., 2017; 3: 524-548
- Gunathilake M.N., Lee J., Choi I.J., Kim Y.I., Ahn Y., Park C., Kim J.: Association between the relative abundance of gastric micro-biota and the risk of gastric cancer: A case control study. Sci. Rep., 2019; 9: 13589
- National Cancer Institute, Surveillance Epidemiology, and End Results Program, https://seer.cancer.gov/statfacts/html/stomach. html (15.06.2020)
- The Cancer Genome Atlas Research Network: Comprehensive molecular characterization of gastric adenocarcinoma. Nature, 2014; 513: 202-209
- Seekatz A.M., Schinzlein M.K., Koenigsknecht M.J., Baker J.R., Hasler W.L., Bleske B.E., Young V.B., Sun D.: Spatial and temporal analysis of the stomach and smallintestinal microbiota in fasted healthy humans. mSphere, 2019; 4: e00126-19
- Nardone G., Compare D.: The human gastric microbiota: Is it time to rethink the pathogenesis of stomach diseases? United European Gastroenterol. J., 2015; 3: 255-260
- Sheh A., Fox J.G.: The role of the gastrointestinal microbiome in Helicobacter pylori pathogenesis. Gut Microbes, 2013; 4: 505-531
- Bassis C.M., Erb-Downward J.R., Dickson R.P., Freeman C.M., Schmidt T.M., Young V.B., Beck J.M., Curtis J.L., Huffnagle G.B.: Analysis of the upper respiratory tract microbiotas as the source of the lung and gastric microbiotas in healthy individuals. mBio, 2015; 6: e00037
- Malinowska M., Tokarz-Deptuła B., Deptuła W.: Mikrobiom człowieka. Post. Mikrobiol., 2017; 56: 33-42
- Rośniak-Bąk K., Pawłowska A., Paradowski M.: Helicobcter pylori: Cechy biochemiczne i patogenne bakterii oraz metody rozpoznawania zakażeń. Diagn. Lab., 2008; 44: 371-378
- Swora E., Stankowiak-Kulpa H., Marcinkowska E., Grzymisławski M.: Kliniczne aspekty diagnostyki zakażenia Helicobacter pylori. Now. Lek., 2009; 78: 228-230
- Minalyan A., Gabrielyan L., Scott D., Jacobs J., Pisegna J.R.: The gastric and intestinal microbiome: Role of proton pump inhibitors. Curr. Gastroenterol. Rep., 2017; 19: 42
- Brawner K.M., Kumar R., Serrano C.A., Ptacek T., Lefkowitz E., Morrow C.D., Zhi D., Kyanam-Kabir-Baig K.R., Smythies L.E., Harris P.R., Smith P.D.: Helicobacter pylori infection is associated with an altered gastric microbiota in children. Mucosal Immunol., 2017; 10: 1169-1177
- Noto J.M., Peek R.M.Jr.: The gastric microbiome, its interaction with Helicobacter pylori, and its potential role in the progression to stomach cancer. PLoS Pathog., 2017; 13: e1006573
- Ermolenko E., Varsin S., Baryshnikova N., Svarval A., Ferman R., Besedina N., Zakrevskaya A., Molostova A., Suvorov A.: Gastrointestinal dysbiosis accompanied of Helicobacter pylori infection and its correction by probiotic. J. Clin. Gastroenterol. Treat., 2018; 4: 055
- Eun C.S., Kim B.K., Han D.S., Kim S.Y., Kim K.M., Choi B.Y., Song K.S., Kim Y.S., Kim J.F.: Differences in gastric mucosal microbiota profiling in patients with chronic gastritis, intestinal meta-plasia, and gastric cancer using pyrosequencing methods. Helicobacter, 2014; 19: 407-416
- Aviles-Jiminez F., Vazquez-Jiminez F., Medrano-Guzman R., Mantilla A., Torres J.: Stomach microbiota composition varies between patients with non-atrophic gastritis and patients with intestinal type of gastric cancer. Sci. Rep., 2014; 4: 4202
- Hu Y.L., Pang W., Huang Y., Zhang Y., Zhang C.J.: The gastric microbiome is perturbed in advanced gastric adenocarcinoma identified through shotgun metagenomics. Front. Cell. Infect. Microbiol., 2018; 8: 433
- Ferreira R.M., Pereira-Marques J., Pinto-Ribeiro I., Costa J.L., Carneiro F., Machado J.C., Figueiredo C.: Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota. Gut, 2018; 67: 226-236
- Castaño-Rodríguez N., Goh K.L., Fock K.M., Mitchell H.M., Kaakoush N.O.: Dysbiosis of the microbiome in gastric carcinogenesis. Sci. Rep., 2017; 7: 15957
- Yang I., Woltemate S., Piazuelo M.B., Bravo L.E., Yepez M.C., Romero-Gallo J., Delgado A.G., Wilson K.T., Peek R.M., Correa P., et al.: Different gastric microbiota compositions in two human populations with high and low gastric cancer risk in Colombia. Sci. Rep., 2016; 6: 18594
- Hsieh Y.Y., Tung S.Y., Pan H.Y., Yen C.W., Xu H.W., Lin Y.J., Deng Y.F., Hsu W.T., Wu C.S., Li C.: Increased abundance of Clostridium and Fusobacterium in gastric microbiota of patients with gastric cancer in Taiwan. Sci. Rep., 2018; 8: 158
- Coker O.O., Dai Z., Nie Y., Zhao G., Cao L., Nakatsu G., Wu W.K., Wong S.H., Chen Z., Sung J.J., Yu J.: Mucosal microbiome dysbiosis in gastric carcinogenesis. Gut, 2018; 67: 1024-1032
- de Leeuw M.A., Duval M.X.: The presence of periodontal pathogens in gastric cancer. Explor. Res. Hypothesis Med., 2020; 5: 87-96
- Salazar C.R., Francois F., Li Y., Corby P., Hays R., Leung C., Bedi S., Segers S., Queiroz E., Sun J., et al.: Association between oral health and gastric precancerous lesions. Carcinogenesis, 2012; 33: 399-403
- Sun J.H., Li X.L., Yin J., Li Y.H., Hou B.X., Zhang Z.: A screening method for gastric cancer by oral microbiome detection. Oncol. Rep., 2018; 39: 2217-2224
- Wu J., Xu S., Xiang C., Cao Q., Li Q., Huang J., Shi L., Zhang J., Zhan Z.: Tongue coating microbiota community and risk effect on gastric cancer. J. Cancer, 2018; 9: 4039-4048
- Eusebi L.H., Zagari R.M., Bazzoli F.: Epidemiology of Helicobacter pylori infection. Helicobacter, 2014; 19: 1-5
- Kuklińska U., Łasica A.M., Jagusztyn-Krynicka E.K.: Białko CagA Helicobacter pylori – pierwsza zidentyfikowana bakteryjna onkoproteina. Post. Mikrobiol., 2011; 50: 97-106
- Mégraud F., Bessède E., Varon C.: Helicobacter pylori infection and gastric carcinoma. Clin. Microbiol. Infect., 2015; 21: 984-990
- Meng C., Bai C., Brown T.D., Hood L.E., Tian Q.: Human gut microbiota and gastrointestinal cancer. Genomics Proteomics Bio-informatics, 2018; 16: 33-49
- Cheung K.S., Leung W.K.: Long-term use of proton-pump inhibitors and risk of gastric cancer: A review of the current evidence. Therap. Adv. Gastroenterol., 2019; 12: 1756284819834511
- Correa P.: Human gastric carcinogenesis: A multistep and multi-factorial process – First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res., 1992; 52: 6735-6740
- Zhao Y., Zhang J., Cheng A.S., Yu J., To K.F., Kang W.: Gastric cancer: Genome damaged by bugs. Oncogene, 2020; 39: 34273442
- Bień S.: Rola infekcji wirusem Epsteina i Barr w schorzeniach głowy i szyi. Pol. Przegl. Otorynolaryngol., 2013; 2: 127-136
- Bocian J., Januszkiewicz-Lewandowska D.: Zakażenia EBV – cykl życiowy, metody diagnostyki, chorobotwórczość. Postępy Hig. Med. Dośw., 2011; 65: 286-298
- Żuk-Wasek A.: Charakterystyka białek wirusa Epsteina-Barr – ich udział w zakażeniu latentnym i powiązanie z procesami nowotworzenia. Post. Mikrobiol., 2012; 51: 191-201
- Polakovicova I., Jerez S., Wichmann I.A., Sandoval-Bórquez A., Carrasco-Véliz N., Corvalán A.H.: Role of microRNAs and exosomes in Helicobacter pylori and Epstein-Barr virus associated gastric cancers. Front. Microbiol., 2018; 9: 63
- Bruno G., Zaccari P., Rocco G., Scalese G., Panetta C., Porowska B., Pontone S., Severi C.: Proton pump inhibitors and dysbiosis: Current knowledge and aspects to be clarified. World J. Gastroenterol., 2019; 25: 2706-2719
- Doorakkers E., Lagergren J., Engstrand L., Brusselaers N.: Helicobacter pylori eradication treatment and the risk of gastric adenocarcinoma in a Western population. Gut, 2018; 67: 2092-2096
- Arora N., Majumer K., Gupta A.: Gastric cancer and the microbiome. Asian Pac. J. Trop. Dis., 2015; 5: 353-35
- Wong B.C., Lam S.K., Wong W.M., Chen J.S., Zheng T.T., Feng R.E., Lai K.C., Hu W.H., Yuen S.T., Leung S.Y, et al.: Helicobacter pylori eradication to prevent gastric cancerin a high-risk region of China: A randomized controlled trial. JAMA, 2004, 291: 187-194
- Stauning A.T., Nordestgaard R.L.M., Frandsen T.H., Andersen L.P.: Gastric microbiota and resistance to antibiotics. In: Helicobacter Pylori - New Approaches of an Old Human Microorganism, eds.: B.M. Roesler. IntechOpen, London 2018
- Brusselaers N., Wahlin K., Engstrand L., Lagergren J.: Maintenance therapy with proton pump inhibitors and risk of gastric cancer: A nationwide population-based cohort study in Sweden. BMJ Open, 2017; 7: e017739
- Peng Y.C., Huang L.R., Lin C.L., Hsu W.Y., Chang C.S., Yeh H.Z., Kao C.H.: Association between proton pump inhibitors use and risk of gastric cancer in patients with GERD. Gut, 2019; 68: 374376
- Kim J.J.: Upper gastrointestinal cancer and reflux disease. J. Gastric Cancer, 2013; 13: 79-85
- Parsons B.N., Ijaz U.Z., D’Amore R., Burkitt M.D., Eccles R., Lenzi L., Duckworth C.A., Moore A.R., Tiszlavicz L., Varro A., et al.: Comparison of the human gastric microbiota in hypochlorhydric states arising as a result of Helicobacter pylori-induced atrophic gastritis, autoimmune atrophic gastritis and proton pump inhibitor use. PLoS Pathog., 2017; 13: e1006653
- Shi Y.C., Cai S.T., Tian Y.P., Zhao H.J., Zhang Y.B., Chen J., Ren R.R., Luo X., Peng L.H., Sun G., Yang Y.S:. Effects of proton pump inhibitors on the gastrointestinal microbiota in gastroesophageal reflux disease. Genomics Proteomics Bioinformatics, 2019; 17: 52-63
- Zhang B., Ling T., Zhaxi P., Cao Y., Qian L., Zhao D., Kang W., Zhang W., Wang L., Xu G., Zou X.: Proton pump inhibitor pantoprazole inhibits gastric cancer metastasis via suppression of telomerase reverse transcriptase gene expression. Cancer Lett., 2019; 452: 23-30
DOI: https://doi.org/10.2478/ahem-2021-0008 | Journal eISSN: 1732-2693
Language: English
Page range: 611 - 619
Submitted on: Aug 13, 2020
Accepted on: Jan 19, 2021
Published on: Nov 29, 2021
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
Related subjects:
© 2021 Magdalena Dzikowiec, Dorota Pastuszak-Lewandoska, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.